|
https://www.sec.gov/Archives/edgar/data/1539029/000156459019… Clearside Biomedical Announces Third Quarter 2019 Financial Results and Provides Corporate Update – Recent Partnerships Support the Broad Applicability of Suprachoroidal Space Injection Platform to Potentially Treat Multiple Ocular Diseases – – Suprachoroidal Axitinib IND Submission Targeted for Mid-2020 – – Management to Host Webcast and Conference Call Today at 4:30 P.M. ET – |
|
| aus der Diskussion: | CLSD (Mkap $39 M) (Cash $65 M) NDA bei der FDA eingereicht =200%+ Chance |
| Autor (Datum des Eintrages): | Sugar2000 (06.11.19 22:59:23) |
| Beitrag: | 860 von 1,108 (ID:61857372) |
| Alle Angaben ohne Gewähr © wallstreetONLINE | |